World's Best Scientists 2026 revealed!
Bonaventura Clotet

Bonaventura Clotet

Award Badge
Immunology
Spain
2026
Award Badge
Medicine
Spain
2023

D-Index & Metrics

Immunology

D-Index
118
Citations
59316
World Ranking
351
National Ranking
3

Medicine

D-Index
118
Citations
59405
World Ranking
4018
National Ranking
55

Bonaventura Clotet publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Bonaventura Clotet sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 1,016 publications — 99th percentile

99% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Bonaventura Clotet D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Bonaventura Clotet sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 118 D-Index — 93rd percentile

93% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Research.com Recognitions

  • 2026 - Research.com Immunology in Spain Leader Award
  • 2025 - Research.com Immunology in Spain Leader Award
  • 2023 - Research.com Medicine in Spain Leader Award
  • 2022 - Research.com Immunology in Spain Leader Award

Overview

Bonaventura Clotet is affiliated with IrsiCaixa in Spain and has a substantial record of research contributions primarily in the field of Medicine. Their work extensively covers infectious diseases, virology, molecular biology, immunology, and epidemiology. The scientist's publication count in these subfields includes 252 papers on Infectious Diseases, 59 on Virology, 41 on Molecular Biology, 41 on Immunology, and 40 on Epidemiology.

The main topics investigated by Clotet encompass a range of areas related to viral infections and their clinical aspects, including:

  • SARS-CoV-2 and COVID-19 Research
  • COVID-19 Clinical Research Studies
  • HIV Research and Treatment
  • SARS-CoV-2 detection and testing
  • HIV/AIDS Research and Interventions
  • HIV/AIDS drug development and treatment
  • Long-Term Effects of COVID-19

Their recent publications include:

  • "Mpox in people with advanced HIV infection: a global case series" (2023), published in The Lancet
  • "Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study" (2021), published in The Lancet Infectious Diseases
  • "Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled Trial" (2020), published in Clinical Infectious Diseases
  • "Use of antiviral drugs to reduce COVID-19 transmission" (2020), published in The Lancet Global Health
  • "A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19" (2020), published in New England Journal of Medicine

Clotet frequently collaborates with several co-authors, including:

  • Julià Blanco
  • Jorge Carrillo
  • Nuria Izquierdo-Useros
  • Roger Paredes
  • Benjamin Trinité

The scientist has also published extensively in certain prominent venues, such as:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • Scientific Reports
  • Frontiers in Immunology
  • Viruses
  • Journal of Antimicrobial Chemotherapy

Best Publications

  • Update of the Drug Resistance Mutations in HIV-1.

    Victoria A Johnson;Francoise Brun-Vezinet;Bonaventura Clotet;Huldrych F Gunthard

  • Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy

    Alison J. Rodger;Valentina Cambiano;Tina Bruun;Pietro Vernazza

  • Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

    Roy M. Gulick;Jacob Lalezari;James Goodrich;Nathan Clumeck

  • Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

    Roy T. Steigbigel;David A. Cooper;Princy N. Kumar;Joseph E. Eron

  • Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.

    Adriano Lazzarin;Bonaventura Clotet;David Cooper;Jacques Reynes

  • Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an international AIDS society-USA panel

    Martin S. Hirsch;Françoise Brun-Vézinet;Richard T. D'Aquila;Scott M. Hammer

  • Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management

    M S Hirsch;B Conway;R T D'Aquila;V A Johnson

  • Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

    Adriano Lazzarin;Thomas Campbell;Bonaventura Clotet;Margaret Johnson

  • Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.

    Martin S. Hirsch;Françoise Brun-Vézinet;Bonaventura Clotet;Brian Conway

  • Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

    Bonaventura Clotet;Nicholas Bellos;Jean Michel Molina;David Cooper

  • Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection: 2008 Recommendations of an International AIDS Society-USA Panel

    Martin S. Hirsch;Huldrych F. Günthard;Jonathan M. Schapiro;Francoise Brun-Vezinet

  • HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

    Maria J Buzón;Marta Massanella;Josep M Llibre;Anna Esteve

  • Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

    Bonaventura Clotet;Judith Feinberg;Jan Van Lunzen;Marie Aude Khuong-Josses

  • Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.

    David A. Cooper;Roy T. Steigbigel;Jose M. Gatell;Jurgen K. Rockstroh

  • Autoantibodies neutralizing type I IFNs are present in ~ 4% of uninfected individuals over 70 years old and account for ~ 20% of COVID-19 deaths.

    Paul Bastard;Adrian Gervais;Adrian Gervais;Tom Le Voyer;Tom Le Voyer;Jérémie Rosain;Jérémie Rosain

  • Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

    David A. Margolis;Juan Gonzalez-Garcia;Hans Jürgen Stellbrink;Joseph J. Eron

  • Update of the Drug Resistance Mutations in HIV-1: 2005.

    Victoria A. Johnson;Françoise Brun-Vézinet;Bonaventura Clotet;Brian Conway

  • Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study

    Linda Wittkop;Huldrych F Günthard;Frank de Wolf;David Dunn

  • Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.

    Calvin J Cohen;Jaime Andrade-Villanueva;Bonaventura Clotet;Jan Fourie

  • Gut Microbiota Linked to Sexual Preference and HIV Infection.

    Marc Noguera-Julian;Marc Noguera-Julian;Muntsa Rocafort;Yolanda Guillén;Javier Rivera

  • Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials

    Charles B Hicks;Pedro Cahn;David A Cooper;Sharon L Walmsley

Frequent Co-Authors

Lidia Ruiz
Lidia Ruiz IrsiCaixa
Eugenia Negredo
Eugenia Negredo University of Vic - Central University of Catalonia
Julià Blanco
Julià Blanco IrsiCaixa
Javier Martinez-Picado
Javier Martinez-Picado University of Vic - Central University of Catalonia
Roger Paredes
Roger Paredes University of Vic - Central University of Catalonia
José A. Esté
José A. Esté Autonomous University of Barcelona
José M. Gatell
José M. Gatell University of Barcelona
Vincent Soriano
Vincent Soriano Universidad Internacional De La Rioja
Miguel Angel Martínez
Miguel Angel Martínez Autonomous University of Barcelona
Pere Domingo
Pere Domingo Autonomous University of Barcelona

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related healthcare degrees can open diverse career opportunities. Nursing programs, especially accelerated pathways, provide a strong foundation in patient care, which complements knowledge in immunological sciences.

Many students find that programs like accelerated FNP offer a rapid route to becoming family nurse practitioners, integrating clinical skills with immunology expertise. For non-nurses looking to enter the field, online accelerated nursing programs for non nurses provide accessible pathways to obtain essential nursing credentials without prior experience.

When choosing nursing programs, some prefer easier admissions as a starting point. Options like the easiest ABSN to get into can make the transition smoother, helping students quickly gain a Bachelor of Science in Nursing. Similarly, exploring easy admission LPN programs can be a practical pathway for those aiming to enter the healthcare workforce with licensed practical nurse credentials, complementing immunology-focused roles.

These diverse online degree options enable students and professionals to tailor their education towards impactful careers in healthcare and immunology research, fostering both clinical and scientific expertise.

Best Scientists Citing Bonaventura Clotet

Trending Scientists

Recently Published Articles